Skip to main content
. 2017 Feb 21;8(13):21754–21769. doi: 10.18632/oncotarget.15567

Figure 5. The anti-proliferative effect is reduced by specific FOXM1-silencing in CRC cells.

Figure 5

Cells were transiently transfected with a siRNA control (si-C) and a specific siRNA FOXM1 (si-FOXM1) for 24 h and was analyzed: A. FOXM1 and β-catenin expression in untreated Caco-2 cells by inmmunofluorescence. Merged images of β-catenin and DAPI staining are also shown. Final magnification: X400 and, B. FOXM1 expression was analized by immunoblotting in whole cell lysates. The expression level of β-actin was included as loading control. C. Cells were transiently transfected with siRNA control (si-C) and a specific si-FOXM1 for 24 hours and then treated with celecoxib (50 μM) and cetuximab (100 μg/ml). The cell proliferation inhibition was determined after 72 hours of treatment using the incuCyte ZOOM® Software 2015A. Data are means ± SEM of three independent experiments (*p <0.05, compared with si-C-transfected cells).